Is Alexander's (ALX) Outperforming Other Finance Stocks This Year?
Here is how Alexander's (ALX) and Healthpeak (DOC) have performed compared to their sector so far this year.
ALX - Alexander's, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$212.00
DETAILS
HIGH:
$212.00
LOW:
$212.00
MEDIAN:
$212.00
CONSENSUS:
$212.00
DOWNSIDE:
21.54%
Stock News
Best Momentum Stocks to Buy for August 11th
DINO, QUAD and ALX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 11, 2026.
New Strong Buy Stocks for August 11th
ALX, DINO, OPBK, CYD and HLLY have been added to the Zacks Rank #1 (Strong Buy) List on August 11, 2026.
Best Income Stocks to Buy for August 11th
ALX, SHIP and QUAD made it to the Zacks Rank #1 (Strong Buy) income stocks list on August 11, 2026.
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer – – Presented encouraging Phase 1b/2 breast cancer data at ESMO Breast Cancer 2026 that further validate a biomarker-driven development strategy for evorpacept – – Strong enrollment momentum in Phase 1 clinical trial of ALX2004 in EGFR expressing solid tumors with initial safety data on-track for 2H 2026 – – Strengthened leadership team with the appointments of Scott Garland as Chairman of the Board of Directors and Michael Listgarten as General Counsel – SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.
Alexander's (ALX) Upgraded to Strong Buy: Here's Why
Alexander's (ALX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Alexander's Q2 Earnings Call Highlights
Vornado Realty Trust reported second-quarter comparable funds from operations of $0.67 per share, up from $0.56 a year earlier, as leasing gains at its PENN District properties, signage revenue and New York office and retail performance contributed to growth.
Alexander's (ALX) Beats Q2 FFO and Revenue Estimates
Alexander's (ALX) came out with quarterly funds from operations (FFO) of $3.02 per share, beating the Zacks Consensus Estimate of $3 per share. This compares to FFO of $2.88 per share a year ago.
Alexander's Announces Second Quarter Financial Results
PARAMUS, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (New York Stock Exchange: ALX) filed its Form 10-Q for the quarter ended June 30, 2026 today and reported:
Alexander's Declares Quarterly $4.50 Dividend on Common Shares
PARAMUS, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on August 28, 2026 to stockholders of record on August 10, 2026.
Alexander's Announces Second Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call
PARAMUS, N.J., July 21, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended June 30, 2026 with the U.S. Securities and Exchange Commission and issue its second quarter earnings release on Monday, August 3, 2026, before the New York Stock Exchange opens.
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, announced that the Compensation Committee of the Board of Directors of ALX Oncology approved the granting of an inducement stock option to purchase a total of 500,000 shares of ALX Oncology's common stock to Michael Listgarten, General Counsel, on June 29, 2026 in connection with the commencement of his employment. Mr. Listgarten's inducement stock option is subject to the terms of the ALX Oncology Holdings Inc. 2025 Inducement Equity Incentive Plan and related forms of agreements, and was granted as an inducement material to Mr. Listgarten to enter into employment with ALX Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel
Strengthens Leadership with Veteran Executives with Decades of Industry Experience Scott Garland Succeeds Co-Founder Corey Goodman, Ph.D., After More Than a Decade of Foundational Leadership SOUTH SAN FRANCISCO, Calif.
Alexander’s Leases 135,000 Square Feet to Target at its Rego Park Shopping Center; Center is 99% Leased
PARAMUS, N. J. , June 29, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) announced today that it has completed a 15-year lease (with renewal options) with Target Corporation at its Rego Park Shopping Center located on Junction Blvd at the Long Island Expressway, in the middle of densely populated Queens, New York.
Alexander's Leases 135,000 Square Feet to Target at its Rego Park Shopping Center; Center is 99% Leased
PARAMUS, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) announced today that it has completed a 15-year lease (with renewal options) with Target Corporation at its Rego Park Shopping Center located on Junction Blvd at the Long Island Expressway, in the middle of densely populated Queens, New York.
Greenridge Exploration Fully Exercises Option for 100% Interest in the Carpenter Lake Uranium Project in Athabasca Basin, Saskatchewan
VANCOUVER, British Columbia, June 16, 2026 (GLOBE NEWSWIRE) -- Greenridge Exploration Inc. (“Greenridge” or the “Company”) (CSE: GXP | OTC: GXPLF | FRA: HW3), is pleased to announce that the Company has fulfilled all the obligations of its property option agreement (the “Agreement”) to earn a 100% legal and beneficial interest in the Carpenter Lake Uranium Project (“Carpenter Lake” or the “Project”), located on the southern margin of the Athabasca Basin in northern Saskatchewan, Canada. Greenridge entered into the Agreement in May 2024 with ALX Resources Corp. (“ALX”) and Renegade Gold Inc. (“Renegade” and together with ALX, the “Optionors”) and has since carried out systematic exploration at the Project, including diamond drilling, in 2024, 2025 and 2026.
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in a fireside chat presentation at the 2026 Jefferies Global Healthcare Conference in New York.
Alexander’s Completes Sale of Rego Park I
PARAMUS, N. J. , May 28, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) announced today that it has completed the previously announced sale of its Rego Park I property, located in Queens, New York, to Northwell Health, Inc. The gross sales price was $235.
Alexander's Completes Sale of Rego Park I
PARAMUS, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) announced today that it has completed the previously announced sale of its Rego Park I property, located in Queens, New York, to Northwell Health, Inc.
The Most Hated High Yields On Wall Street
Let's capitalize on analyst incompetence—and bank yields up to 18.3%, with upside to boot!
Price Targets
Alexander's price target raised to $212 from $190 at Piper Sandler
$212.00
(was $281.51)
Alexander Goldfarb
·
Piper Sandler
Alexander's (ALX) PT Lowered to $125 at Piper Sandler
$125.00
(was $217.10)
Alexander Goldfarb
·
Piper Sandler
Alexander's (ALX) PT Lowered to $145 at Piper Sandler
$145.00
(was $216.71)
Alexander Goldfarb
·
Piper Sandler